SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

AnyClip enters insolvency proceedings amid advertising market turmoil

AI growth can’t offset weak guidance at Nice

From defense giants to startups: Israel reconsiders how it buys weapons

Physical AI is breaking the hyperscale model - not because of compute, but because of where compute can exist

Buzz

Most popular

Daily

Weekly

1

Cisco acquires AI security startup Astrix for $400 million

2

Five bidders advance in Nice’s $2.5 billion Actimize sale process

3

Kela raising $200 million at $1 billion valuation with backing from Bill Ackman and Eric Schmidt

4

The 50 most promising Israeli startups - 2026

5

ZyG raises $60 million Series A at $500 million valuation just a year after launch

Mori Arkin

5 stories about Mori Arkin

Exalenz Bioscience Acquired for $49M

19.02.20|Golan Hazani

Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!

Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company

19.02.20|Golan Hazani

Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source

סטפן אושמן מנכ"ל Merck

Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel

20.02.18|Meir Orbach

The incubator program has a five year budget of 20 million euros

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich

The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani

Sol-Gel approached potential underwriters. It aims to go public before the end of the year